CLAIMS

1. A compound of formula (I):



formula (I)

wherein **A** is 6-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms;

X is O, S, S(O), $S(O)_2$ or NR^{14};

m is 0, 1, 2, 3 or 4;

Y is a group selected from O, NR^5CO, $CONR^5$, $CR^6R^7CONR^5$ and $CR^6R^7NR^5$;

Z is a group selected from $-NR^1R^2$, phosphonooxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl (substituted by phosphonooxy) and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;

$\mathbf{R^1}$ is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

$\mathbf{R^2}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

or $\mathbf{R^1}$ and $\mathbf{R^2}$ together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C_{1-4}alkyl substituted by phosphonooxy or $-NR^8R^9$, and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;

R^3 is a group selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;

R^4 is hydrogen or a group selected from C_{1-4}alkyl, heteroaryl, heteroarylC_{1-4}alkyl, aryl and arylC_{1-4}alkyl which group is optionally substituted by 1, 2 or 3 substitutents selected from halo, methyl, ethyl, cyclopropyl and ethynyl;

R^5 is a group selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^6 and R^7 are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;

R^8 is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^9 is selected from hydrogen and C_{1-4}alkyl;

R^{10} is selected from hydrogen and C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonoxy;

R^{11}, R^{12}, R^{13} and R^{14} are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein A is a group of formula (a), (b), (c) or (d):



(a) (b) (c) (d)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I); or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2 wherein A is a group of formula (b) or (d) as defined in claim 2; or a pharmaceutically acceptable salt thereof.

4. A compounds according to any one of claims 1, 2 or 3 wherein X is NH; or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of the preceding claims wherein Z is a group selected from $-NR^1R^2$, phosphonooxy, cyclopropyl which cyclopropyl is substituted by C_{1-}

$_4$alkyl substituted by phosphonooxy, and a piperidine or piperazine ring linked via carbon which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy; or a pharmaceutically acceptable salt thereof.

6. A compound according to any one of the preceding claims wherein R^1 is C_{1-5}alkyl substituted by phosphonooxy and R^2 is hydrogen, C_{1-5}alkyl, C_{2-4}alkynyl or C_{3-6}cycloalkyl; or a pharmaceutically acceptable salt thereof.

7. A compound according to any one of claims 1 to 5 wherein R^1 and R^2 together with the nitrogen to which they are attached form a piperidine, pyrrolidine or piperazine ring which is substituted on carbon or nitrogen by a group selected from phosphonooxy, phosphonooxymethyl and 2-phosphonooxyethyl and where the ring is optionally further substituted on carbon or nitrogen by 1 or 2 methyl.

8. A compound according to any one of the preceding claims wherein R^3 is methoxy or hydrogen; or a pharmaceutically acceptable salt thereof.

9. A compound according to any one of the preceding claims wherein R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro; or a pharmaceutically acceptable salt thereof.

10. A compound selected from:

3-[(3-{[4-({6-[(3-chlorobenzyl)oxy]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;

3-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7 yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3 chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;

2-[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7 yl]oxy}propyl)piperidin-2-yl]ethyl dihydrogen phosphate;

[(2R)-1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)pyrrolidin-2-yl]methyl dihydrogen phosphate;

2-[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl]ethyl dihydrogen phosphate;

2-[ethyl(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3,4-difluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isopropyl)amino]ethyl dihydrogen phosphate;

(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl dihydrogen phosphate;

4-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}butyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;

[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-2-yl]methyl dihydrogen phosphate;

2-[(5-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}pentyl)(ethyl)amino]ethyl dihydrogen phosphate;

4-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]butyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isobutyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclopropyl)amino]ethyl dihydrogen phosphate;

[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl]methyl dihydrogen phosphate;

2-[4-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperazin-1-yl]ethyl dihydrogen phosphate;

[(2*S*)-1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)pyrrolidin-2-yl]methyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclobutyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclohexyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;

3-{[4-({2-[(3-chlorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl dihydrogen phosphate;

1-[3-({4-[(2-{[(3-chloro-4-fluorophenyl)amino]methyl}pyrimidin-5-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl dihydrogen phosphate;

3-[(3-{[4-({2-[(3-chloro-4-fluorobenzyl)oxy]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;

2-[(3-{[4-({2-[(3-chlorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(2,2-dimethylpropyl)amino]ethyl dihydrogen phosphate;

[2-({[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}methyl)cyclopropyl]methyl dihydrogen phosphate; and

2-[4-({[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}methyl)piperidin-1-yl]ethyl dihydrogen phosphate;

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier.

12. Use of a compound according to any one of claims 1 to 10 in therapy.

13. Use of a compound according to any one of claims 1 to 10 in the preparation of a medicament for the treatment of a disease where the inhibition of one or more Aurora kinase is beneficial.

14. Use according to claim 13 wherein Aurora kinase is Aurora-A kinase or Aurora-B kinase.

15. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hyperproliferative diseases such as cancer and in particular colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas.

16. A method of treating a human suffering from a disease in which the inhibition of one or more Aurora kinases is beneficial to the treatment, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

17. A method of treating a human suffering from colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

18. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (II) into a compound of formula (I) by phosphorylation of an appropriate hydroxy group:



formula (II)

where A, X, m, Y, R^3 and R^4 are as defined for formula (I); and **Z'** is a group selected from – $NR^{1'}R^{2'}$, hydroxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by hydroxy or C_{1-4}alkyl substituted by hydroxy, and a 4- to 7-membered ring linked via a carbon atom, containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated and which ring is substituted on carbon or nitrogen by hydroxy or C_{1-4}alkyl substituted by hydroxy and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups; $\mathbf{R^{1'}}$ is a group selected from–

$COR^{8'}$, $-CONR^{8'}R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups; $\mathbf{R^{2'}}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or hydroxy, or $R^{2'}$ is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl; or $\mathbf{R^{1'}}$ and $\mathbf{R^{2'}}$ together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated and which ring is substituted on carbon or nitrogen by a group selected from hydroxy and C_{1-4}alkyl which C_{1-4}alkyl is substituted by hydroxy or $-NR^{8'}R^9$ and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups; and where $\mathbf{R^{8'}}$ is C_{1-4}alkyl substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups:

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I); and/or

ii) removing any protecting groups; and/or

iii) forming a pharmaceutically acceptable salt thereof.